Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Cystic Fibrosis
Interventions
BIOLOGICAL

Alpha-1 HC 100 mg

Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.

BIOLOGICAL

Placebo

Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.

BIOLOGICAL

Alpha-1 HC 200 mg

Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.

Trial Locations (6)

27599

UNC at Chapel Hill, Chapel Hill

29425

Medical University of South Carolina, Charleston

35233

The University of Alabama at Birmingham, Birmingham

44106

Rainbow Babies and Children's Hospital, Cleveland

80206

National Jewish Hospital, Denver

02115

Children's Hospital Boston, Boston

Sponsors
All Listed Sponsors
lead

Grifols Therapeutics LLC

INDUSTRY